Denali Therapeutics (DNLI)
(Delayed Data from NSDQ)
$30.24 USD
-0.67 (-2.17%)
Updated Sep 23, 2024 03:59 PM ET
After-Market: $30.23 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
DNLI 30.24 -0.67(-2.17%)
Will DNLI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DNLI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DNLI
Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?
Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?
DNLI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?
Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug
Why Is BioMarin (BMRN) Up 5.4% Since Last Earnings Report?
Other News for DNLI
Denali Therapeutics price target raised by $4 at BofA, here's why
Buy Rating Affirmed: FDA’s Endorsement and Promising Data Bolster Denali Therapeutics’s Drug Pipeline
Denali Therapeutics: Strong Buy on Regulatory Wins and ETV Franchise Progress
Denali to file for FDA accelerated approval of DNL310 in early 2025
Denali Therapeutics’ DNL310 Shows Promise for Early Approval and Market Success